文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

成人超重或肥胖药物比较效果:系统评价与网状Meta分析

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2026-07-08
一句话结论一年时替尔泊肽、CagriSema、口服司美格鲁肽等减重幅度最大但不良事件与停药更多,仅皮下司美格鲁肽与替尔泊肽显示部分心血管获益。

该系统评价与网状Meta分析纳入262项随机对照试验、99 791名成人超重或肥胖者,评估19种药物,随访12至172周,采用频率学派随机效应模型、贝叶斯剂量反应模型与GRADE分级。与单纯生活方式干预相比,一年时替尔泊肽减重-14.9%、CagriSema -14.8%、口服司美格鲁肽-10.9%等,中至高确定性;但胃肠道事件、疲劳与因不良事件停药风险因药而异。皮下司美格鲁肽是唯一与全因死亡(RR 0.81)和心肌梗死(RR 0.72)下降相关的药物,皮下司美格鲁肽与替尔泊肽降低心衰风险。多数药物未显著改善生活质量,临床决策需权衡获益与危害并共享决策。

要点

  • 与生活方式干预相比,一年时替尔泊肽减重-14.9%(95%CI -16.0%至-13.9%)、CagriSema -14.8%(-16.9%至-12.7%),为中至高确定性证据。
  • 口服司美格鲁肽-10.9%、orforglipron -9.9%、皮下司美格鲁肽-9.8%、芬特明-托吡酯-8.1%,均为中至高确定性。
  • 因不良事件停药风险最高者为orforglipron、纳曲酮-安非他酮、利拉鲁肽、芬特明-托吡酯、CagriSema、口服司美格鲁肽(RR 1.9–4.2)。
  • 疲劳风险以纳曲酮-安非他酮(RR 8.9,一年每1000人绝对增加331)、orforglipron(RR 3.4,每1000人增加100)、CagriSema(RR 3.2,每1000人增加92)最明显。
  • 皮下司美格鲁肽是唯一与全因死亡(RR 0.81,95%CI 0.72–0.93)和心肌梗死(RR 0.72,0.61–0.85)下降相关者,证据主要来自高危人群心血管结局试验。

适用人群与场景

  • 成人超重或肥胖者;纳入12周及以上的随机对照试验,比较一种或多种药物与生活方式干预、安慰剂或另一种药物
  • 随访12至172周;原文未提及急诊或ICU场景及具体纳入排除标准

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体给药剂量、途径、频次或目标值;仅报告各药一年时相对生活方式干预的减重幅度与风险比
  • 决策应在共享决策框架下权衡获益与危害

红旗征与不能漏的情况

  • 因不良事件停药风险最高:orforglipron、纳曲酮-安非他酮、利拉鲁肽、芬特明-托吡酯、CagriSema、口服司美格鲁肽(RR 1.9–4.2)
  • 胃肠道事件增加最明显:纳曲酮-安非他酮、口服司美格鲁肽、orforglipron、替尔泊肽(RR 3.1–4.2)
  • 疲劳风险增加尤其见于纳曲酮-安非他酮、orforglipron、CagriSema

研究设计与关键结果

  • 系统评价与网状Meta分析,纳入262项随机对照试验、99 791名参与者、19种药物,随访12至172周,采用频率学派随机效应模型、贝叶斯剂量反应模型与GRADE分级
  • 主要终点为一年时体重变化百分比:替尔泊肽-14.9%(95%CI -16.0%至-13.9%)、CagriSema -14.8%(-16.9%至-12.7%)、口服司美格鲁肽-10.9%(-12.7%至-9.1%)、orforglipron -9.9%(-12.4%至-7.5%)、皮下司美格鲁肽-9.8%(-10.6%至-9.1%)、芬特明-托吡酯-8.1%(-9.7%至-6.5%),中至高确定性
  • 新兴药物ecnoglutide、mazdutide、retatrutide可能减重13.1–14.6%(极低至低确定性)
  • 皮下司美格鲁肽降低全因死亡(RR 0.81,95%CI 0.72–0.93)和心肌梗死(RR 0.72,0.61–0.85);皮下司美格鲁肽(RR 0.43,0.21–0.84)与替尔泊肽(RR 0.49,0.27–0.88)降低心衰风险

证据类型、等级与局限

  • 证据类型:系统评价与网状Meta分析(262项RCT),采用GRADE分级与Cochrane RoB 2工具
  • 局限性:原文未明确列出;设计上部分结果为极低至低确定性(新兴药物),心血管获益估计主要来自高危人群心血管结局试验,生活质量分析仅43项试验

对床旁实践的改变

  • 对超重或肥胖成人选择药物时,应将一年减重幅度与停药、胃肠道事件、疲劳等危害一并权衡,而非仅看减重数字
  • 皮下司美格鲁肽是目前唯一显示全因死亡与心肌梗死下降的药物,但证据主要来自高危人群心血管结局试验,不适用于外推至所有人群
  • 不应期望多数药物显著改善生活质量(平均差异均<5分,低于最小重要差异10分)
  • 原文未提及急诊或ICU场景下的具体做法改变

指南或共识出处

  • 原文未提及具体指南或共识名称;系统评价注册号PROSPERO CRD42024507993

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients.

DESIGN: Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool.

DATA SOURCES: Medline, Embase, and Cochrane Library, searched up to 12 November 2025.

STUDY SELECTION: Randomised controlled trials of 12 weeks' duration or longer comparing one or more drugs with lifestyle modification, placebo, or another drug.

RESULTS: This network meta-analysis comprised 262 trials (99 791 participants) evaluating 19 drugs with follow-up from 12 to 172 weeks. Compared with lifestyle modification alone, at one year, moderate to high certainty evidence shows substantial weight loss with tirzepatide (mean difference -14.9%, 95% confidence interval -16.0% to -13.9%), cagrilintide-semaglutide (CagriSema, -14.8%, -16.9% to -12.7%), oral semaglutide (-10.9%, -12.7% to -9.1%), orforglipron (-9.9%, -12.4% to -7.5%), subcutaneous semaglutide (-9.8%, -10.6% to -9.1%), and phentermine-topiramate (-8.1%, -9.7% to -6.5%). Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce similar or greater reductions (13.1-14.6%; very low to low certainty). Moderate to high certainty evidence supports discontinuation because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2); gastrointestinal events were most increased with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2). Fatigue risk increased, particularly with naltrexone-bupropion (risk ratio 8.9; absolute increase 331 per 1000 people over one year), orforglipron (3.4; 100 more per 1000), and CagriSema (3.2; 92 more per 1000). Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%). Subcutaneous semaglutide was the only drug associated with reduced all cause mortality (risk ratio 0.81, 95% confidence interval 0.72 to 0.93) and myocardial infarction (0.72, 0.61 to 0.85), with these estimates largely informed by cardiovascular outcome trials in high risk populations. Subcutaneous semaglutide (0.43, 0.21 to 0.84) and tirzepatide (0.49, 0.27 to 0.88) reduced heart failure risk. No drugs convincingly reduced kidney failure or improved quality of life (43 trials with 45 663 participants) beyond established minimally important differences (all mean differences <5 points; minimally important difference 10). Except for larger weight reductions in trials with longer duration (shown for subcutaneous semaglutide), subgroup analyses for drug dosages and key patient characteristics did not identify credible differences in relative effects of treatment.

CONCLUSIONS: Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation. Most agents do not improve quality of life meaningfully and few show cardiovascular benefits. Decisions in clinical practice should consider trade-offs between benefits and harms within the context of shared decision making.

SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024507993.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. PMID: 42419792. doi:10.1136/bmj-2026-372161

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。